Weekly subcutaneous atacicept 150 mg vs. placebo in 428 adults with biopsy-confirmed IgA nephropathy (214 per group) over 104 weeks (ORIGIN 3 phase 3 RCT), evaluating eGFR change at week 52, annualized eGFR slope through week 104, composite kidney-disease progression, and safety.
At week 52, mean eGFR change was -0.11 vs. -5.69 mL/min/1.73 m² (difference +5.58; P<0.001). Through week 104, annualized eGFR slope was -0.60 vs. -5.60 mL/min/1.73 m²/year (difference +5.00; P<0.001). Composite kidney-disease progression occurred in 5.1% (atacicept) vs. 17.8% (placebo) — hazard ratio 0.24 (95% CI 0.12–0.48; P<0.001); 0 vs. 7 patients progressed to dialysis, transplantation, or death.
Trial duration was 2 years, so very long-term kidney outcomes (beyond week 104) remain unknown. The trial enrolled adults only, limiting generalizability to pediatric IgA nephropathy. Background standard-of-care therapies were not uniformly described in the abstract, making it harder to isolate atacicept's effect in real-world practice.
Atacicept 150 mg weekly SC nearly halted eGFR decline over 2 years and cut kidney-disease progression events by ~76% vs. placebo — clinicians managing IgA nephropathy patients at risk of progression should consider this as a potential disease-modifying option. Serious adverse events were lower with atacicept (7.0%) than placebo (15.4%), suggesting a favorable safety profile.